Medications for opioid use disorder: bridging the gap in care.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

50 citing papers in PubMed, 5 syntheses or guidelines pooled it.

1. Factors associated with the percentage of individuals who initiate and discontinue naltrexone as a relapse prevention pharmacotherapy in opioid use disorder: A systematic review, meta-analysis and meta-regression.Addiction (Abingdon, England) · 2026
   Pooled it
2. A review of the kappa opioid receptor system in opioid use.Neuroscience and biobehavioral reviews · 2024
   Pooled it
3. Interventions for hospitalized medical and surgical patients with opioid use disorder: A systematic review.Substance abuse · 2022
   Pooled it
4. Global patterns of opioid use and dependence: harms to populations, interventions, and future action.Lancet (London, England) · 2019
   Pooled it
5. Smartphone Apps Targeting Alcohol and Illicit Substance Use: Systematic Search in in Commercial App Stores and Critical Content Analysis.JMIR mHealth and uHealth · 2019
   Pooled it
6. Prescribers' satisfaction with delivering medications for opioid use disorder.Substance abuse treatment, prevention, and policy · 2021
   Trial
7. Within-subject evaluation of interim buprenorphine treatment during waitlist delays.Drug and alcohol dependence · 2021
   Trial
8. Effects of lorcaserin on oxycodone self-administration and subjective responses in participants with opioid use disorder.Drug and alcohol dependence · 2020
   Trial
9. Trajectory classes of opioid use among individuals in a randomized controlled trial comparing extended-release naltrexone and buprenorphine-naloxone.Drug and alcohol dependence · 2019
   Trial
10. Physicians' satisfaction with providing buprenorphine treatment.Addiction science & clinical practice · 2019
    Trial
11. Randomized pilot trial of Web-based cognitive-behavioral therapy adapted for use in office-based buprenorphine maintenance.Substance abuse · 2019
    Trial
12. Accounting for the uncounted: Physical and affective distress in individuals dropping out of oral naltrexone treatment for opioid use disorder.Drug and alcohol dependence · 2018
    Trial
13. "The alternative is they're not getting care at all": a qualitative interview study of opioid use disorder treatment providers' perspectives on quality and appropriateness of telehealth for buprenorphine access.Harm reduction journal · 2026
    Article
14. Improving access to oral health care for patients with opioid use disorder: Dentists' perspectives on barriers and solutions.Journal of the American Dental Association (1939) · 2026
    Article
15. The rising tide of opioid use disorder: analyzing 30 years of epidemiological trends and socioeconomic factors in the U.S.Naunyn-Schmiedeberg's archives of pharmacology · 2026
    Article
16. Engaging veterans in the development of mobile health interventions to support medication treatment for opioid use disorder.Frontiers in digital health · 2026
    Article
17. "Now that I'm here, I actually have the stability and the time to really think about stuff like that": Perspectives on medications for opioid use disorder in low-threshold harm reduction housing.Journal of substance use and addiction treatment · 2025
    Article
18. Understanding the use of telemedicine across different opioid use disorder treatment models: A scoping review.Journal of telemedicine and telecare · 2025
    Article
19. Buprenorphine use among non-hospital residential programs.Drug and alcohol dependence · 2024
    Article
20. Alternative Reinforcers Enhance the Effects of Opioid Antagonists, but Not Agonists, on Oxycodone Choice Self-Administration in Nonhuman Primates.The Journal of pharmacology and experimental therapeutics · 2024
    Article

Corrections and comments

• Comment on
  Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): a multicentre, open-label, randomised controlled trial.2018

Authors and funding

1 author.

Funding

Abstract

PubMed holds no abstract for this paper.

Indexed as